Finance and treasury in a pharmaceutical company is among the most complex financial management challenges in any industry. Drug development pipelines require multi-billion-dollar capital commitments with highly uncertain and long-dated returns. Revenue is concentrated in a small number of commercial products, often with patent cliff exposure. Foreign exchange, tax structure, and capital markets management each add layers of financial complexity.
The pharma CEO is ultimately accountable for financial performance and must maintain meaningful oversight of financial strategy. At the same time, the depth and complexity of pharmaceutical finance is such that the operational management of every financial function must be delegated to a capable Chief Financial Officer and their team.
Defining the CEO-CFO Partnership
The most important delegation in pharmaceutical finance is not a delegation in the conventional sense. It is a partnership. The CEO and CFO must operate as aligned strategic partners, with the CFO providing the financial expertise and the CEO providing the strategic and operational context that guides financial decision-making.
The CEO’s financial responsibilities are: setting financial strategy in alignment with organizational mission and pipeline priorities, making major capital allocation decisions, maintaining investor and board confidence in financial management, and engaging with the most significant financial counterparties at the executive level.
The CFO’s responsibilities are: managing all financial operations, producing accurate and timely financial reporting, overseeing treasury and capital markets activity, managing relationships with banks and financial advisors, directing the tax and audit functions, and providing the CEO with the financial analysis needed for strategic decisions.
This partnership requires trust and clear communication, not the CEO’s operational involvement in financial management.
Delegating Financial Reporting and Controllership
Financial reporting, including preparation of financial statements, oversight of the accounting close process, and management of internal controls, is the CFO’s domain entirely. A Controller or Chief Accounting Officer manages the day-to-day accounting function, and the CFO reviews and owns financial reporting quality.
The CEO reviews financial reports after they are prepared and engages with financial results at the level of strategic implications: Is revenue performance aligned with commercial strategy? Are R&D expenses tracking against the planned pipeline investment? Are operating margins reflecting the commercial model assumptions that underlie strategic planning?
The CEO is not in the accounting process. They are reviewing the output of that process and interpreting it strategically.
Delegating Treasury Operations
Treasury management in a pharmaceutical company encompasses cash management, debt and equity capital markets activities, foreign exchange hedging, and investment of cash reserves. A Treasurer, reporting to the CFO, owns these operational responsibilities.
The CEO participates in treasury management at strategic decision points: major debt financing or equity offerings where CEO engagement with banks and investors is appropriate, significant foreign exchange risk management decisions affecting earnings, and capital structure decisions that require board approval.
Between these strategic moments, treasury operations run through the Treasurer and CFO without CEO involvement. Cash positioning, FX hedging execution, short-term investment management, and banking relationship logistics are delegatable operational activities.
Capital Allocation Decision Framework
Capital allocation is one of the highest-stakes decisions a pharmaceutical CEO makes: how much to invest in internal R&D versus business development, how to allocate capital across pipeline stages, when to deploy capital for acquisitions or licensing versus return it to shareholders.
Build a capital allocation decision framework that defines which allocation decisions the CEO makes independently, which require board approval, and which can be delegated to the CFO or business units within pre-approved parameters.
Annual R&D budget allocation within board-approved ranges can be managed through the strategic planning process led by the CEO and CFO jointly. Project-level resource allocation within approved budgets can be delegated to the CMO and R&D leadership. Major capital deployments above a defined threshold require CEO and board approval.
This framework prevents the CEO from being pulled into every financial allocation discussion while ensuring they are engaged at the strategic decision points that genuinely matter.
For guidance on how capital allocation connects to the broader pharma CEO delegation framework, see pharma CEO delegation guide.
Managing Investor Relations
Investor relations is a function with significant CEO involvement requirements, but the operational infrastructure should be entirely delegated. A Head of Investor Relations manages: quarterly earnings call logistics and presentation preparation, ongoing analyst relationship management, investor conference scheduling and coordination, and the production of investor-facing materials.
The CEO leads investor communications at the strategic level: earnings calls where CEO presence is required, investor days or analyst days where CEO participation drives investor confidence, major strategic announcements where CEO voice is essential, and relationships with the largest and most strategically significant institutional investors.
The Head of Investor Relations manages analyst relationships, tracks institutional ownership, monitors market perception, and prepares the CEO for every investor engagement with briefing materials and anticipated questions.
Delegating Tax Planning
Tax strategy in a pharmaceutical company involves significant complexity: intellectual property ownership structures, transfer pricing, research tax credits, international tax planning, and compliance across multiple jurisdictions. A VP of Tax or Senior Tax Director should lead the tax function, working closely with the CFO and external advisors.
The CEO is informed of major tax planning decisions and approves structural choices that affect the company’s global footprint or financial relationships. They do not manage tax planning processes or review individual tax positions.
The tax function is one of the most highly delegatable financial functions precisely because it requires such specialized expertise. The CEO’s role is to ensure the right expertise is engaged and that the organization maintains compliance and reputational standards in its tax practices.
Financial Risk Management
Pharmaceutical companies face multiple categories of financial risk: product concentration risk, patent expiration risk, clinical trial failure risk, regulatory risk, and macroeconomic risks including foreign exchange and interest rate exposure. Managing financial risk requires both strategic and operational attention.
The CFO owns financial risk management: maintaining the enterprise risk register, coordinating risk mitigation strategies across functional areas, overseeing insurance programs, and reporting risk to the board audit committee.
The CEO engages with financial risk at the strategic level: ensuring the pipeline diversification strategy manages product concentration risk, approving major risk mitigation investments, and communicating risk management approach to investors and the board.
Audit Committee Relationship
The audit committee of the board has a governance relationship with the CFO and external auditors that is largely independent of the CEO. The audit committee oversees financial reporting quality, internal controls, and the auditor relationship on behalf of the board.
The CEO participates in audit committee discussions on significant accounting matters and financial risk, but they are not the primary management interface for audit committee oversight. The CFO leads that relationship.
According to McKinsey, pharmaceutical CFOs who operate as strategic business partners to the CEO, rather than financial reporters, drive significantly higher organizational value through better-calibrated capital allocation, financial risk management, and investor confidence.
Building the CEO-CFO Communication Rhythm
The CEO-CFO communication rhythm should be structured to keep the CEO informed without requiring daily financial briefings. This might include:
A weekly or biweekly briefing from the CFO covering current financial status, any emerging issues, and upcoming financial decisions requiring CEO involvement. Monthly financial performance review with leadership team context on variances and strategic implications. Quarterly investor relations preparation sessions to align on the financial narrative for the quarter. Annual capital allocation and budget review discussions as part of strategic planning.
Between these touchpoints, the CFO manages financial operations independently and escalates only when an issue genuinely requires CEO involvement: a significant accounting matter, a covenant breach scenario, a major capital market opportunity, or a financial risk emerging from the business.
See pharma commercial strategy for how financial performance oversight connects to commercial strategy and business unit accountability at the CEO level.
Conclusion
Pharmaceutical finance is too complex and too consequential for CEO personal management, and too strategically important for CEO disengagement. The right approach is the CEO-CFO partnership model: the CEO owns financial strategy and major capital decisions, the CFO owns financial operations and analysis, and both maintain a regular communication rhythm that keeps the CEO informed and the CFO strategically guided.
Build this partnership, delegate the operational finance functions that the CFO and their team should own, and engage your financial leadership where it matters most: capital allocation, investor confidence, financial risk, and the strategic decisions that determine the company’s long-term financial health.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.